Redwood Investment Management LLC Buys 15,482 Shares of Pfizer Inc. $PFE

Key Points

• Redwood Investment Management LLC increased its holdings in Pfizer Inc. by 25.9%, owning a total of 75,149 shares worth approximately $1.9 million as of the latest SEC filing.
• Other significant institutional investors, including Vanguard Group Inc. and Northern Trust Corp, also raised their positions, contributing to hedge funds owning over 68% of Pfizer's stock.
• Pfizer reported earnings of $0.78 per share for the last quarter, exceeding analyst estimates, with revenue of $14.65 billion, a 10.3% increase compared to the previous year.

Redwood Investment Management LLC raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 25.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,149 shares of the biopharmaceutical company's stock after acquiring an additional 15,482 shares during the quarter. Redwood Investment Management LLC's holdings in Pfizer were worth $1,904,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. boosted its stake in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Nuveen LLC purchased a new position in Pfizer in the first quarter valued at about $389,861,000. Starboard Value LP purchased a new position in Pfizer in the fourth quarter valued at about $407,730,000. Goldman Sachs Group Inc. boosted its stake in Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after purchasing an additional 7,581,030 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Pfizer stock traded up $0.16 during midday trading on Wednesday, reaching $25.08. 31,814,192 shares of the stock were exchanged, compared to its average volume of 44,824,848. The company's fifty day moving average is $24.76 and its 200-day moving average is $24.40. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $142.57 billion, a PE ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Finally, Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.